PET imaging to support the development of multimodal incretin agonists

Antaros Medical is proud to have contributed to a new high-impact paper in Cell Metabolism describing the development of a potential unimolecular GLP-1/GIP/GCG receptor triagonist for treatment of metabolic diseases. The contribution from Antaros Medical comes from the work of Olof Eriksson (Director, PET Imaging), Lars Johansson (CSO) and Stefan Pierrou (Director, Clinical Trial Management) who have done a fantastic job in providing insights on target engagement of the individual components of this trimodal incretin agonist using PET imaging. Insights on target engagement are vital for the development of novel multimodal incretin agonist.

Antaros Medical’s proprietary incretin PET tracers supports development of multimodal incretin agonists

Antaros Medical has extensive experience in both driving imaging science and delivering clinical trials in diabetes, obesity, and metabolism. We have proprietary PET tracers for the gastric inhibitory polypeptide (GIP) and glucagon (GCG) receptors. They form, together with an additional PET-tracer for the glucagon like peptide-1 (GLP-1) receptor, a powerful tool set for tailoring solutions measuring receptor occupancy of multimodal incretin agonists developed for the treatment of various metabolic disorders. This PET-tracer tool set can provide data to help set dosing and to provide evidence that the investigated drug hits several targets as intended. This also includes understanding the overlapping pharmacology of activating the different incretin receptors with multi-agonist peptides. These PET tracers are an important platform for moving new metabolic treatments forward.

Find the publication in Cell Metabolism here:

Title: Effect of weight loss and glycemic control with SAR441255 a potential unimolecular GLP-1/GIP/GCG receptor triagonist

Authors: M Bossart, M Wagner, R Elvert, A Evers, T Hübschle, T Kloeckener, K Lorenz, C Moessinger, O Eriksson, I Velikyan, S Pierrou, L Johansson, G Dietert, Y Dietz-Baum, T Kissner, I Nowotny, C Einig, C Jan, F Rharbaoui, J Gassenhuber, H-P Prochnow, I Agueusop, N Porksen, WB. Smith, A Nitsche, A Konkar

If you want to read more publications around our incretin PET tracers you can find some below:

Title: Glucagon Like Peptide-1 receptor imaging in individuals with Type 2 Diabetes

Authors: Eriksson O, Velikyan I, Haack T, Bossart M, Laitinen I, Larsen PJ, Berglund JE, Antoni G, Johansson L, Pierrou S, Tillner J, Wagner M

Title: Drug Occupancy Assessment at the Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor by Positron Emission Tomography

Authors: Eriksson O, Velikyan I, Haack T, Bossart M, Evers A, Lorenz K, Laitinen I, Larsen P J, Plettenburg O, Johansson L, Pierrou S, Wagner M

Title: Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes

Authors: O Eriksson, T Haack, Y Hijazi, L Teichert, V Tavernier, I Laitinen, J-E Berglund, G Antoni, I Velikyan I, L Johansson, S Pierrou, M Wagner, J Tillner

Share on Linkedin Share on Twitter